Cagrilintide (CAS?1415456?99?3) – Purity?99.17% GMP Factory

描述

Cagrilintide is an investigational long-acting acylated analogue of amylin that functions as a dual agonist at amylin receptors (AMYR) and calcitonin receptors (CTR). It triggers dose-dependent reduction in food intake and significant weight loss in preclinical and human trials. Used alone or combined with GLP?1 analogues, it shows enhanced metabolic effects in obesity and type 2 diabetes studies.
This research-grade peptide is manufactured in GMP?compliant peptide synthesis facilities, validated to ?99.17% purity by HPLC, and supplied with a Certificate of Analysis (COA) for traceability. Supplied as lyophilized powder.
?? For laboratory research use only—not approved for clinical or therapeutic use.

Product Specifications

Mechanism of Action & Research Applications

Cagrilintide acts on amylin and calcitonin receptors to slow gastric emptying, reduce appetite, and drive weight loss. Clinical and phase II trials show around 10–15% weight loss over 26–32 weeks, especially when combined with GLP?1 analogues like semaglutide.
Ideal research uses include:

• Obesity and weight loss modeling

• Appetite and satiety signaling assays

• Combination studies with GLP?1 analogues

• Metabolic syndrome and type 2 diabetes research

• GPCR pharmacology involving amylin/calcitonin receptor pathways

Side Effects (For Laboratory Reference Only)

Observed effects may include:

• Gastrointestinal symptoms (e.g. nausea, reduced appetite)

• Dose-dependent weight reduction

• Mild adverse events similar to GLP?1 therapies
  Careful dosing and monitoring in animal or clinical research protocols.

Disclaimer

This peptide is intended exclusively for laboratory research use. It is not approved for clinical, therapeutic, or diagnostic applications in humans or animals.